Can Emcure’s Cut-Price Eribulin Dull Halaven In India?
Executive Summary
Emcure has launched a generic version of Eisai’s cancer drug Halaven on the Indian market at a sharp 40% discount to the innovator product, and hopes to expand patient access significantly.
You may also be interested in...
Roche Bolsters India Partnering With Cipla, Entero To Handle Nephrology
Roche is pressing ahead with partnering deals in India as part of efforts to expand access to certain key existing brands and signals intent to continue to explore more collaborations wherever it needs to “reach out to more patients urgently.”
Do Not Be So Quick To Blame Microbes On The Lab, The US FDA Warns Emcure
Emcure's Hinjwadi, India, plant should have investigated other more likely sources of contamination more thoroughly, the FDA says.
India’s Emcure Launches First Generic of Eisai's Halaven, Changing Pricing Scenario
Indian drug company Emcure says it is launching the first generic version of Japanese drugmaker Eisai's Halaven which targets metastatic breast cancer and will undercut the branded drug’s price in the country by nearly half.